^
    Back
    Association details:
    Biomarker:GNAQ Q209P
    Cancer:Melanoma
    Drug:PLX4720 (BRAF inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Ann Oncol
    Title:

    Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition

    Excerpt:
    When GNAQQ209P was expressed in A375 cells (supplementary Figure S7, available at Annals of Oncology online), it increased basal ERK phosphorylation and reduced ERK sensitivity to PLX4720 (Figure ​(Figure3C)3C) and, critically, it also reduced the sensitivity of A375 cells to PLX4720 (Figure ​(Figure3D).3D).
    DOI:
    10.1093/annonc/mdu049